ROBENGATOPE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROBENGATOPE is an injectable pharmaceutical product approved in 1971 as a New Drug Application (NDA) by Bracco. The specific mechanism of action, pharmacologic class, and approved indications are not publicly documented in available sources. The product is administered via injection and has a legacy status approaching loss of exclusivity.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting shrinking brand team and focus on transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring velocity on ROBENGATOPE. Working on this product offers experience in lifecycle management, generic transition planning, and cost containment strategies rather than brand-building or innovation opportunities.
Brand ManagerProduct Manager
Worked on ROBENGATOPE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.